During the second half of the twentieth century the pharmaceutical industry made an increasingly significant contribution to the national economies not only of the two countries figuring in this book, the USA and Germany, but also to those of many others, including Japan, Britain and France as well as to the growth of international trade and business. Over the same period, there was increasing government regulation concerning the safety and efficacy of pharmaceutical products in many countries. However, relatively few detailed explorations of the development of safety regulation have been published, so this comparative study of the development of the regulatory frameworks in the USA and Germany between 1950 and 2000 is very welcome.

The parameters of the study and its main focus---the politics of regulation---are established in the first chapter. Arthur Daemmrich sets out to explore regulation *vis-à-vis* therapeutic cultures, the term he uses to encompass the complexity of the relationships which have developed between those primarily, although in varying degrees, concerned: "the state (including legislatures and regulatory agencies), the pharmaceutical industry, the medical profession, and disease-based organizations" (p. 4). However, as the later chapters and the drug case studies evidence, the existence and role in the process of disease-based organizations is largely confined to the USA and there it is seen most clearly in the case of HIV/AIDS.

The study as a whole makes it clear that differences of history, of political systems, of ways of delivering healthcare and of professional medical approaches have resulted not only in a lack of disease-based organizations in Germany, comparable to those of the USA, but also in the development of the very different regulatory regimes revealed in this book. To summarize the major difference, in the USA regulatory authority rests solely with the state, whereas in Germany it is shared across a network of state, industry and the medical profession.

Case studies on the adoption and use of terramycin, thalidomide and propanolol are used to highlight and explain the development of different systems in the two countries over the period 1950 to 1980. Thalidomide was, of course, the trigger for increasing regulation in the shape of more stringent testing requirements before new drugs could be launched on the market in the USA and in many European countries. Although the USA escaped the worst effects of thalidomide because the FDA did not license it, the new requirements imposed took a longer time to meet and that impacted significantly on the introduction of propanolol; the discussion of this provides a strong contrast with the use of propanolol in Germany.

By 1980 pre-clinical and clinical trials had become an institutionalized process in drug development, a phenomenon explored at work in the later chapters, which focus on the last two decades of the twentieth century. The cases of the cancer therapy, interleukin-2 and the anti-AIDS drug, indinavir are used to illustrate and explore the nature of post-market drug introduction surveillance as well as the changing nature of the major relationships. In the final chapter the attempts to create an internationally harmonized regulatory system and the implications of such a system are discussed. Given the strength of national differences in the politics of medicine and perceptions of the patient, highlighted in this book, as articulated through the regulatory systems, now deeply embedded, it is hardly surprising that international harmonization encounters resistance.

It is no criticism of this significant and highly readable comparison of regulatory development in the USA and Germany, to suggest that further studies extending the comparison to other significant drug-producing and consuming countries would enhance our understanding.
